The House included $10M for Endometrial Cancer Research in the FY2027 defense appropriations bill but funding needs to make it to the final package. Show lawmakers why endometrial cancer research funding should be priority: sgo.org/news/sgo-launches-en… #FundEndometrialCancerResearch
Mark retweeted
🔬 New real-world data on #OvarianCancer surgery!
Which works better: 🔪 Primary or 💉Interval Debulking?
🩺 In 929 pts with stage III–IV EOC:
📈 Primary debulking → ⬆️ OS (68.4 vs 52 mo, p = .0004)
📉 BUT no significant difference after adjustment (HR 1.15, p = .12)
💡 Key takeaways:
👩⚕️ Younger, Stage III, BRCA-WT/HRP → 💪 benefit from primary
🧬 BRCA-mut/HRD → 🔄 similar outcomes with either approach ♻️
📌 Personalized surgery is the way forward!
🔗 bit.ly/4k1caVt
@pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @RParejaGineOnco @lchiv4 @annafagottimd @HousseinELHAJJ3 @AinhoaMada @HelenaObermair @sofiabigardiGMD @marina_rosanu @ChakraRim @FilippoCapom @mcgouveia_
#IJGConline #Research #Treatment #Diagnostic #GynCancer #GynOnc #WomenHealth #SoMe #SoMe4GynOnc
I am privileged to have presented our real-world analysis of Nab Paclitaxel versus Paclitaxel in the PROC setting alongside my colleagues and collaborators from Corcept Therapeutics and Flat Iron Database at the ESMO GYN 2025 meeting today.
Mark retweeted
Holy shit, these San Diego residents kicking ICE the fuck out of their neighborhood.
THIS IS POWERFUL.✊💪
xitter.cf/juliesCamp/status/1929…
Mark retweeted
🚨NEW: New York Attorney General Letitia James has announced she will be suing the Trump Administration over his illegal freezing of federal aid, becoming the first official in the U.S. to take action.
RETWEET to thank @TishJames for standing up for our democracy!
Mark retweeted
#HPVVaccine saves lives
"Imagine if you had a daughter and she was diagnosed with #cervicalcancer and you could have protected her from it and you chose not to ..."
Powerful Video by Laura Brennan #IGCS2024 #CervixCancer
Big thanks to @AhmedAHefnawy for sharing.
Presidential plenary session dedicated to eradicating cervix cancer! Don’t forget to vaccinate. We have an opportunity to eliminate cervical cancer
#IGCS2024
An excellent review for uterine transposition. Giving our cancer patients options to preserve the uterus and retain fertility option.
Robin Cohen, CEO of Sandy Rollman Ovarian Cancer Foundation speaking on The Every Woman Study: low and middle income edition.
#IGCS2024
Mark retweeted
Congratulations Dr Cloven presenting quality of life data from the RUBY trial at #IGCS2024
Mark retweeted
#IGCS2024 🇮🇪🍀late breaking abstract
Durvalumab + carboplatin/paclitaxel followed by durvalumab +/- olaparib for EC: MMRD &/or MSI-high subpopulation efficacy analyses from the DUO-E trial
#gyncancer
@IGCSociety @RiosDoriaMD @abigailflynt @IJGConline
Mark retweeted
“At the top of the ballot, Harris does deserve our vote. She offers us a way forward lit by rationality and respect for all. Economically, the renewable-energy projects she supports will create new jobs in rural America. Her platform also increases tax deductions for new small businesses from
$5,000 to $50,000, making it easier for them to turn a profit. Trump, a convicted felon who was also found liable of sexual abuse in a civil trial, offers a return to his dark fantasies and demagoguery, whether it’s denying the reality of climate change or the election results of 2020 that were confirmed by more than 60 court cases, including some that were overseen by judges whom he appointed.
“One of two futures will materialize according to our choices in this election. Only one is a vote for reality and integrity. We urge you to vote for Kamala Harris.”
For only the second time in our 179-year history, the editors of Scientific American are endorsing a candidate for president. That person is @KamalaHarris. | Editorial bit.ly/4daH36q
40 Percent of Cancer Cases and Almost Half of All Cancer Deaths in the United States Linked to Modifiable Risk Factors - The ASCO Post ascopost.com/news/july-2024/…
Great day to visit some of my colleagues in Florida while having the honor of presenting the latest advances presented at ASCO 2024. Spreading the word and elevating quality of care for women with gynecologic cancers.
Making progress for endometrial cancer subtypes! One more step forward
Long-term follow-up of efficacy and safety of #selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study
@ASCO #ASCO24 @GOG @Karyopharm sciencedirect.com/science/ar…










































